{
    "organizations": [],
    "uuid": "f325a5069ee5b3aab193f38498ef74624ee86463",
    "author": "",
    "url": "https://www.reuters.com/article/brief-revance-provides-update-on-anticip/brief-revance-provides-update-on-anticipated-clinical-milestones-and-financial-outlook-for-2018-idUSASB0BZR6",
    "ord_in_thread": 0,
    "title": "BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 44 PM / in 12 minutes BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018 Reuters Staff \nJan 4 (Reuters) - Revance Therapeutics Inc: \n* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018 \n* REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018 \n* REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION \n* REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION Source text for Eikon:  ",
    "published": "2018-01-04T15:42:00.000+02:00",
    "crawled": "2018-01-04T16:02:03.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "provides",
        "update",
        "anticipated",
        "clinical",
        "milestone",
        "financial",
        "outlook",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "revance",
        "therapeutic",
        "inc",
        "revance",
        "provides",
        "update",
        "anticipated",
        "clinical",
        "milestone",
        "financial",
        "outlook",
        "revance",
        "therapeutic",
        "inc",
        "expects",
        "complete",
        "rt002",
        "sakura",
        "phase",
        "program",
        "start",
        "rt002",
        "phase",
        "trial",
        "cervical",
        "dystonia",
        "revance",
        "therapeutic",
        "inc",
        "expects",
        "cash",
        "burn",
        "range",
        "million",
        "revance",
        "therapeutic",
        "inc",
        "anticipates",
        "gaap",
        "research",
        "development",
        "expense",
        "range",
        "million",
        "source",
        "text",
        "eikon"
    ]
}